glp 1/gip The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology GLP-1 and GIP in Type

Research shows that GLP-1 effectively reduces neuroinflammation by decreasing pro-inflammatory cytokine release and inhibiting microglia activation

Additionally, weight loss with semaglutide was associated with improvements in cardiovascular risk factors and physical fitness

Improvements seem related reductions in fat and inflammation Al-Aly said when he looks at his results, he thinks the drugs probably act via two different pathways

Whether a proportional or threshold anti-inflammatory effect exists at microdose levels remains an open question

Both promised convenience, medical oversight, and real results, but I wanted to see which one actually delivered on those claims